Holen Sie sich die Stockscreener-App
18.96
0.13%
0.02
Schlusskurs vom Vortag:
$18.94
Offen:
$18.97
24-Stunden-Volumen:
663.89K
Relative Volume:
0.28
Marktkapitalisierung:
$2.42B
Einnahmen:
$642.82M
Nettoeinkommen (Verlust:
$-43.54M
KGV:
-54.23
EPS:
-0.3496
Netto-Cashflow:
$130.12M
1W Leistung:
-8.87%
1M Leistung:
+4.66%
6M Leistung:
+50.04%
1J Leistung:
+91.95%
1-Tages-Spanne:
$18.90
$19.82
1-Wochen-Bereich:
$18.80
$21.25
52-Wochen-Spanne:
$6.78
$23.56
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, TEM, BTSG, HQY, WAY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
18.92 | 2.42B | 642.82M | -43.54M | 130.12M | -0.3496 |
|
VEEV
Veeva Systems Inc
|
179.27 | 29.72B | 3.20B | 908.91M | 1.42B | 5.4155 |
|
TEM
Tempus Ai Inc
|
50.54 | 8.85B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
38.16 | 7.42B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
76.83 | 6.56B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
24.15 | 4.72B | 1.10B | 112.09M | 283.19M | 0.6096 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Eingeleitet | Piper Sandler | Neutral |
| 2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
Cathie Wood’s ARK trims 10X Genomics stock, adds DraftKings - Investing.com
Level Four Advisory Services LLC Acquires New Position in 10x Genomics $TXG - MarketBeat
Smart Money: Can 10x Genomics Inc grow without dilutionWeekly Trend Summary & Breakout Confirmation Alerts - baoquankhu1.vn
Risk Report: Can 10x Genomics Inc grow without dilutionJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
10x Genomics $TXG Shares Bought by JPMorgan Chase & Co. - MarketBeat
Citigroup Inc. Increases Holdings in 10x Genomics $TXG - MarketBeat
ARK Investment Cuts Stake in 10x Genomics - National Today
10x genomics CEO Saxonov sells $367,096 in shares - Investing.com UK
10x Genomics $TXG Shares Sold by ARK Investment Management LLC - MarketBeat
Amova Asset Management Americas Inc. Has $62.86 Million Stock Holdings in 10x Genomics $TXG - MarketBeat
Life Sciences Tools & Services Stocks Q4 In Review: 10x Genomics (NASDAQ:TXG) Vs Peers - Finviz
10x Genomics (TXG) CEO sells shares and makes stock gift - Stock Titan
10x Genomics $TXG Position Lifted by Vanguard Group Inc. - MarketBeat
10X Genomics Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Breaking Down 10x Genomics: 11 Analysts Share Their Views - Sahm
Commit To Buy 10x Genomics At $15, Earn 20.6% Annualized Using Options - Nasdaq
TXG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
10x Genomics, Inc. (TXG) Stock Analysis: A Closer Look at the Healthcare Innovator’s Growth Potential and Analyst Ratings - DirectorsTalk Interviews
Stifel Nicolaus Boosts 10x Genomics Price Target to $25 - National Today
Major RSU grant to 10x Genomics (TXG) CEO Serge Saxonov - Stock Titan
88,816 RSUs awarded to 10x Genomics (TXG) director Hindson - Stock Titan
10x Genomics (TXG) CFO granted 106,579 RSUs in new equity award - Stock Titan
TXG affiliate files Form 144: proposed Class A Common sale (NASDAQ: TXG) - Stock Titan
10X Genomics Hits Day High with Strong 12.56% Intraday Surge - Markets Mojo
10x Genomics (NASDAQ:TXG) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Is It Time To Reassess 10x Genomics (TXG) After Its 1 Year Share Price Surge - Yahoo Finance
10x Genomics (NASDAQ:TXG) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Is 10x Genomics Inc.’s ROIC above industry averageTrade Performance Summary & AI Driven Price Forecasts - mfd.ru
Insider Sell: Sarah Teichmann Sells Shares of 10x Genomics Inc (TXG) - GuruFocus
Director at 10x Genomics (TXG) sells 7,579 shares under 10b5-1 plan - Stock Titan
10x Genomics (TXG) Price Target Increased by 10.28% to 20.33 - Nasdaq
10x Genomics (NASDAQ:TXG) CEO Serge Saxonov Sells 9,632 Shares of Stock - MarketBeat
10x Genomics (TXG) CEO sells 9,632 shares to cover RSU tax - Stock Titan
[Form 4] 10x Genomics, Inc. Insider Trading Activity - Stock Titan
10x Genomics (TXG) officer sells 7,826 shares to cover RSU tax - Stock Titan
10x Genomics, Inc. (TXG) Stock Analysis: Navigating Growth Potential In Health Information Services - DirectorsTalk Interviews
Vestmark Advisory Solutions Inc. Sells 340,854 Shares of 10x Genomics $TXG - MarketBeat
Insider sale filing for TXG (NASDAQ: TXG) lists 8,301 shares on 02/23/2026 - Stock Titan
TXG (NASDAQ: TXG) insider sale notice: 25,784 RSU shares listed for sale - Stock Titan
Issuer insider sale notice — 23,767 shares (NASDAQ: TXG) - Stock Titan
Is 10x Genomics Inc. (1KJ) stock positioned for secular growthRecession Risk & Expert Curated Trade Ideas - mfd.ru
TXG: UBS Raises Price Target for 10x Genomics to $20 | TXG Stock News - GuruFocus
10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference - BioSpace
5 Must-Read Analyst Questions From 10x Genomics's Q4 Earnings Call - Finviz
GSA Capital Partners LLP Buys 106,167 Shares of 10x Genomics $TXG - MarketBeat
162,202 Shares in 10x Genomics $TXG Bought by Principal Financial Group Inc. - MarketBeat
10x Genomics Stock Climbs as Analysts Signal Growth Prospects - StocksToTrade
10x Genomics’ Growth Prospects Brightened by Strategic Advances - timothysykes.com
10x Genomics Cancer Alliances Test AI Ambitions Against Mixed Share Performance - Yahoo Finance
10x Genomics Sees Bullish Momentum Following Revenue Projections and Price Target Upgrades - StocksToTrade
10x Genomics Sees Bullish Momentum with Raised Price Targets - timothysykes.com
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
0.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):